These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27022633)

  • 41. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The design and use of cluster randomised controlled trials in evaluating injury prevention interventions: part 2. Design effect, sample size calculations and methods for analysis.
    Coupland C; DiGuiseppi C
    Inj Prev; 2010 Apr; 16(2):132-6. PubMed ID: 20363822
    [No Abstract]   [Full Text] [Related]  

  • 43. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 44. Issues in the planning and conduct of randomised trials.
    Bhandari M; Pape HC; Giannoudis PV
    Injury; 2006 Apr; 37(4):349-54. PubMed ID: 16487524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic Evaluation of the Robustness of the Evidence Supporting Current Guidelines on Myocardial Revascularization Using the Fragility Index.
    Gaudino M; Hameed I; Biondi-Zoccai G; Tam DY; Gerry S; Rahouma M; Khan FM; Angiolillo DJ; Benedetto U; Taggart DP; Girardi LN; Crea F; Ruel M; Fremes SE
    Circ Cardiovasc Qual Outcomes; 2019 Dec; 12(12):e006017. PubMed ID: 31822120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A statistic to avoid being misled by the "winners curse".
    Tugwell P; Knottnerus JA
    J Clin Epidemiol; 2018 Nov; 103():vi-viii. PubMed ID: 30293635
    [No Abstract]   [Full Text] [Related]  

  • 47. Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level.
    Rombach I; Gray AM; Jenkinson C; Murray DW; Rivero-Arias O
    BMC Med Res Methodol; 2018 Aug; 18(1):87. PubMed ID: 30153796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Yes, size does matter!: Sample size calculations for randomised trials.
    Middleton L
    BJOG; 2020 Jul; 127(8):1016-1017. PubMed ID: 31910329
    [No Abstract]   [Full Text] [Related]  

  • 49. Learning From Major Clinical Trials: Bending Without Breaking.
    Pfeffer MA
    Circulation; 2017 Dec; 136(23):2207-2209. PubMed ID: 29203564
    [No Abstract]   [Full Text] [Related]  

  • 50. Randomizing 1 eye or 2 eyes: a missed opportunity.
    Glassman AR; Melia M
    JAMA Ophthalmol; 2015 Jan; 133(1):9-10. PubMed ID: 25256889
    [No Abstract]   [Full Text] [Related]  

  • 51. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
    Rasmussen HE; Ma R; Wang JJ
    Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of randomized controlled trials: issues to consider when designing a trial.
    Pandis N
    Am J Orthod Dentofacial Orthop; 2013 Jun; 143(6):905-7. PubMed ID: 23726342
    [No Abstract]   [Full Text] [Related]  

  • 53. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
    Chen CT; Hung HM; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiplicity in oncology randomised controlled trials: a threat to medical evidence?
    Prasad V; Booth CM
    Lancet Oncol; 2019 Dec; 20(12):1638-1640. PubMed ID: 31797779
    [No Abstract]   [Full Text] [Related]  

  • 55. Factorial trials in cardiology: pros and cons.
    Lubsen J; Pocock SJ
    Eur Heart J; 1994 May; 15(5):585-8. PubMed ID: 8055995
    [No Abstract]   [Full Text] [Related]  

  • 56. Statistical aspects of design and analysis of clinical trials for the prevention of caries.
    Burnside G; Pine CM; Williamson PR
    Caries Res; 2006; 40(5):360-5. PubMed ID: 16946602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statistical efficiency in multiple-to-one comparison trials with optimal allocation ratio.
    Zhang J; Zhang JJ
    J Biopharm Stat; 2011 Jan; 21(1):125-35. PubMed ID: 21191859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multi-period crossover trials.
    Matthews JN
    Stat Methods Med Res; 1994 Dec; 3(4):383-405. PubMed ID: 7889228
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical trials methodology: randomization, intent-to-treat, and random-effects regression.
    Atkins DC
    Depress Anxiety; 2009; 26(8):697-700. PubMed ID: 19658122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.